
Older adults had comparable sacituzumab govitecan outcomes and severe toxicity in a selected real-world cohort
AI-summarized from the linked source. Educational brief, not medical advice.
Brief summary
Across 18 Central European oncology centers, 76 adults age 65 or older receiving sacituzumab govitecan had response, treatment-modification, and grade 3 or higher neutropenia outcomes comparable to younger patients, while age was not independently associated with survival after adjustment.
What NurseJet pulled from the source
This retrospective multinational cohort included 303 adults with metastatic triple-negative breast cancer treated with sacituzumab govitecan, including 76 age 65 or older. Older patients had more comorbidities, more prior palliative treatment, and poorer performance status. Their unadjusted survival appeared longer, but age was not independently associated with overall or progression-free survival in multivariable models. Objective response, disease control, treatment modifications, and grade 3 or higher neutropenia were comparable by age. The authors attributed the unadjusted survival differences to baseline characteristics and selection rather than age itself.
Why this matters for nurses
Oncology nurses monitor treatment tolerance, laboratory trends, infection risk, and the practical effects of comorbidity and performance status. These data support individualized assessment rather than assuming that chronological age alone predicts poor tolerance or benefit.
Bedside takeaway
Selected older adults had comparable real-world outcomes and severe neutropenia, so tolerance assessment should extend beyond age alone.
How This Applies in Practice
Use this when: Caring for an older adult with metastatic triple-negative breast cancer who is receiving a provider-directed sacituzumab govitecan regimen.
On your shift
- Review ordered laboratory results, current symptoms, comorbidities, functional status, and recent treatment interruptions before administration.
- Assess for infection or treatment intolerance and escalate fever, clinical deterioration, or abnormal results through the oncology team promptly.
- Document tolerance trends and how symptoms affect function so dose and supportive-care decisions reflect more than chronological age.
Explain this for my unit
Key takeaways
- The real-world cohort included 303 patients treated at 18 oncology centers, with 76 patients age 65 or older.
- Response, disease control, treatment modifications, and grade 3 or higher neutropenia were comparable between age groups.
- Chronological age was not independently associated with overall or progression-free survival after adjustment.
- The selected older group and retrospective design limit conclusions about frailer adults or causal treatment effects.
Practice implications
- Review ordered blood counts and current symptoms before treatment, assess how comorbidities and functional status affect the care plan, and escalate fever, infection concerns, or suspected treatment toxicity promptly. Communicate trends and treatment interruptions so the oncology team can make patient-specific dosing and supportive-care decisions.
Limitations & cautions
- This was a retrospective study of a selected treated population across Central European centers, and only 76 patients were age 65 or older. Age 65 does not capture frailty, selection into treatment may explain apparent similarities, and residual confounding remains. The abstract reports severe neutropenia but does not provide a complete age-stratified adverse-event profile.
- AI-summarized from the linked source. Review the original article before applying to practice.
Citations
Exact source links
Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.
The Oncologist (PubMed)
The Oncologist (PubMed). Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study.
https://pubmed.ncbi.nlm.nih.gov/42477865/
Professional education only


